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ABSTRACT 
Use of active forms of vitamin D is advocated in CKD patients for treatment of mineral bone 
disease because of the presumption that native forms of vitamin D would not undergo 
significant activation to calcitriol, the most active biological form of vitamin D. We present 
secondary analysis looking at bone turnover in subjects who completed the randomized, double 
blind, placebo controlled trial investigating the effect of cholecalciferol supplementation on 
vascular function in non­diabetic CKD stage G3­4 and vitamin D ≤20ng/ml 
[CTRI/2013/05/003648]. Patients were randomized (1:1) to receive either two directly 
observed oral doses of 300,000 IU of cholecalciferol or matching placebo at baseline and 8 
weeks.  Of the 120 subjects enrolled, 58 in the cholecalciferol group and 59 in the placebo 
group completed the study. At 16 weeks, the serum 25(OH)D and 1,25(OH)2D levels increased 
in the cholecalciferol group but not in the placebo group [between-group difference in mean 
change: 23.40 ng/ml; 95% CI: 19.76 to 27.06; p<0.001 and 14.98 pg/ml ,95% CI: 4.48 to 27.18, 
p=0.007, respectively]. Intact parathormone (iPTH) decreased in the cholecalciferol group 
[between-group difference in mean change -100.73 pg/ml (95% CI: -150.50 to -50.95, 
p<0.001). Serum total and bone-specific alkaline phosphatase (SAP, BAP) and serum C-
terminal cross-linked collagen type I telopeptides (CTX-1) were significantly reduced in 
cholecalciferol group (between group difference for change in mean: -20.25 U/L (95% CI: -
35.14 to-5.38, p=0.008 for SAP; -12.54, 95%CI: -22.09 to -2.98, p=0.013 for BAP and -0.21, 
95%CI: -0.38 to -0.05, p=0.05 for CTX-1 ). Correlation analysis showed significant correlation 
of Δ 25(OH)D with Δ iPTH (r=-0.409, p<0.0001), Δ 1,25(OH)2D (r=0.305, p=0.001), Δ SAP 
(r=-0.301, p=0.002), ΔBAP (r=-0.264, p=0.004), and ΔCTX-1 (r=-0.210, p=0.0230). 
Cholecalciferol supplementation corrects vitamin D deficiency and is effective in lowering 
serum intact parathyroid hormone and bone turnover markers in early stages of CKD. This 
article is protected by copyright. All rights reserved 
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BACKGROUND 
Mineral and bone disorders (MBD) are common, and start early in the course of chronic kidney 
disease (CKD).(1) Current understanding indicates that vitamin D, calcium, parathyroid 
hormone (PTH), inorganic phosphate and fibroblast growth factor 23 (FGF23) are key players 
in CKD-MBD.(2) Clinical manifestations appear relatively late, but biochemical abnormalities, 
such as elevations in serum phosphate, FGF23 and parathyroid hormone levels  have been 
noted in 3%, 50% and 22% of subjects with eGFR 50-59 ml/min/1.73m2.(3) 
 
Abnormality in vitamin D production is central to the genesis of CKD-MBD. Reduced renal 
1-  hydroxylase activity lowers the levels of activated vitamin D3, and causes an increase in 
PTH secretion. Vitamin D deficiency stimulates the secretion of FGF23 by osteocytes, which 
further contributes to hyperparathyroidism.(4,5) The discovery of 1- hydroxylase activity in 
many tissues, including the parathyroid gland suggests that correction of vitamin D deficiency 
might ameliorate the secondary hyperparathyroidism of CKD by improving substrate 
availability, at least in early stages of the disease. Cross-sectional studies have shown an 
association between circulating vitamin D levels and markers of bone turnover in CKD.(6) 
However, whether correction of vitamin D deficiency will lead to improvement in CKD-MBD 
has not been tested in interventional  studies. 
 
In a pre-specified secondary analysis of randomised double-blind placebo-controlled trial of 
cholecalciferol supplementation in non-diabetic vitamin D deficient subjects with stage 3-4 
CKD, we investigated the effect of oral cholecalciferol supplementation on markers of mineral 
metabolism which included 1,25(OH)2D, FGF23, PTH, serum C-terminal cross-linked 
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METHODS 
Study subjects and biomarker evaluation 
This single centre, parallel arm, randomized, double blind, placebo-controlled trial was done 
at the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 
India. The study was approved by Institute Ethics Committee and all subjects provided written 
informed consent. The detailed study protocol and subject enrolment process has been 
described earlier.(7) Briefly, 120 stable non-diabetic, CKD stage G3-4 subjects of either sex 
between the ages of 18 and 70 years with serum 25(OH)D levels 20 ng/ml were randomised 
in a 1:1 allocation ratio to receive two directly supervised doses of either 300,000 IU of 
cholecalciferol or matching placebo at baseline and 8 weeks later. Randomization was done by 
computer generated Bernoulli random number table, and the investigators as well as the 
patients were blinded.  
 
Serum creatinine, calcium, inorganic phosphorus, lipid profile, uric acid, and haemoglobin 
were measured at baseline and 16-week visits on fasting blood samples. Serum 25(OH)D was 
measured by enzyme immunoassay [EIA; Immunodiagnostic Systems (IDS), UK], certified 
for calculation of 25(OH)D by Center for Disease Control (CDC) Vitamin D Standardization 
Certification Program (VDSCP).(8,9) Serum 1,25(OH)2D (EIA, IDS, UK),  serum intact 
parathyroid hormone (iPTH; EIA, Calbiotech Inc., USA), serum intact fibroblast growth 
factor-23 [FGF-23; second generation enzyme linked immunosorbent assay (ELISA), 
Immutopics, Diagnostic Hybrids Inc., USA], BAP [ MicroVueTM BAP EIA, Quidel 
Corporation San Diego USA] and CTX-1 [Serum CrossLaps® (CTX-1) ELISA, IDS, UK) 
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Outcomes 
We investigated changes in levels of serum levels of  1,25(OH)2D, intact-PTH, intact-FGF23, 
inorganic phosphorus, calcium and SAP, BAP and CTX-1.  
 
Statistical analysis 
Data are  presented as mean ± standard deviation, mean (95% confidence interval) and median 
(interquartile range) as appropriate. Continuous variables were compared with independent 
samples Student’s t test if normally distributed, or with Mann-Whitney U test if the distribution 
was skewed. Categorical variables were analysed by Chi Square test or Fisher’s Exact test as 
appropriate. Paired Student’s t-test and Wilcoxon signed-rank test were used for within-group 
comparisons. Correlation analysis was performed using Spearman’s rank correlation. 
Subgroup analysis based on gender, baseline vitamin D tertiles and age (≤50 years and >50 
years) was performed to see any effect on change in iPTH within subgroups. Interaction 
between intervention and subgroup variables was examined using general linear model. Two 
tailed p-values <0.05 were considered statistically significant. Analyses were conducted using 
the Statistical Package for the Social Sciences (SPSS) software for Macintosh, version 21.0 
(IBM Corp., Armonk, NY, USA).  
 
RESULTS 
Baseline characteristics of the study subjects are shown in Table 1. The demographic details, 
causes of CKD and use of medications were similar in both the groups. Biochemical parameters 
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Change in biochemical parameters and circulating biomarkers 
At 16 weeks, the serum 25(OH)D levels increased in the cholecalciferol group (mean change: 
+24.91 ng/ml; 95% CI: 21.77 to 28.06; p<0.001; table 3) but not in the placebo group (+1.51. 
ng/ml; 95% CI: (-0.46 to 3.48; p=0.13; table 3). The difference in change in 25(OH)D levels 
between the two groups was significant (p<0.001, Table 3, 4). Similarly, serum 1,25(OH)2D 
levels increased in the cholecalciferol (15.46 pg/ml; 95% CI: 5.42 to 25.50, p=0.003) but not 
in placebo group (0.48 pg/ml; 95% CI: -4.65 to 5.62, p=0.85), with significant difference 
between the group for change over 16 weeks (p=0.007).  
 
Serum levels of iPTH showed a significant decline in the cholecalciferol group at 16 weeks  
whereas in placebo group there was a rise. This was accompanied by a significant decrease in 
total SAP, BAP and CTX-1 levels in cholecalciferol group, whereas the levels remained 
unchanged in the placebo treated subjects. The between group difference in change was 
significant for all these markers (Table 3,4). 
 
Though serum level of iFGF23 did show a decreasing trend in the cholecalciferol group, it did 
not reach statistical significance. Change in iFGF23 in the placebo group, and between group 
difference for  change in iFGF23 were not significant. A numeric increase was noted in serum 
calcium in the cholecalciferol group, whereas it decreased significantly in placebo group, 
leading to a significant between-group difference in mean change. Serum uric acid decreased 
in the cholecalciferol-treated subjects but not in placebo group. Serum inorganic phosphorus 
(Pi), serum creatinine, eGFR and hemoglobin levels did not change significantly in either group 
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Correlation analysis for biomarkers of mineral metabolism 
We examined the correlation of change (Δ) in 25 (OH) D levels at baseline and at 16 weeks  
with that in the other markers, and found a significant correlation of Δ 25(OH)D with Δ iPTH 
(r=-0.403, p<0.0001), Δ 1,25(OH)2D (r=0.305, p=0.001), Δ SAP (r=-0.301, p=0.002), ΔBAP 
(r=-0.264, p=0.004), ΔCTX-1 (r=-0.210, p=0.0230), Δ Pi (r=0.220, p=0.019), and Δ Ca 
(r=0.199, p=0.05). ΔiFGF23 correlated with ΔiPTH (r=0.290, p=0.002) but not with Δ 
25(OH)D (r=-0.121, p=0.195). 
 
In subgroup analyses, the change in iPTH remained significant in males, lower tertiles (tertile 
1 and 2) of baseline vitamin D levels and groups based on age (≤50 years and >50 years) with 
no significant heterogeneity of treatment effect on ΔiPTH  across these subgroups (table 5).  
 
DISCUSSION 
This study provides strong evidence that correction of native vitamin D deficiency with 
cholecalciferol supplementation efficiently achieves sufficient level of 25(OH)D in pre-
dialysis CKD subjects and has a favourable effect on several biochemical parameters of CKD-
MBD, including suppression of secondary hypoparathyroidism, change in bone turnover 
markers and favourable trend in FGF-23 levels. Change in serum 25(OH)D level significantly 
correlated with the change in markers of mineral metabolism, indicating that vitamin D 
deficiency is  a potentially modifiable risk factor for bone mineral disease in subjects with stage 
G3-4 CKD.  
 
Vitamin D deficiency has been shown to be associated with hyperparathyroidism and increased 
bone turnover in subjects with CKD, as shown by elevation in CTX-1 and BAP.(6) An 
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Malachi et al reported high level of SAP in vitamin D deficient elderly individuals and decline 
with seasonal rise in vitamin D level. (13)  Other observational studies and randomised trials 
have investigated the effect of Vitamin D supplementation in healthy adults and children. Most 
showed a significant decline in PTH, but the effect on bone formation and resorption markers 
was inconsistent. (14-19) Chandra et al randomized 34 subjects with stage 3-4 CKD and 25(OH) 
D level <30 ng/ml to receive weekly 50,000 IU cholecalciferol or placebo for 12 week. There 
was a decrease in the week 12 iPTH levels, but there was no difference in the levels of bone 
turnover markers. (20)  
 
Despite the efficacy of cholecalciferol supplementation in reducing iPTH levels in subjects 
with pre-dialysis CKD,(21,22) recent studies have focussed on activated vitamin D analogues.(23) 
The findings of the present study show that a sufficient level of circulating 25(OH) D in 
subjects with CKD is important to restrict PTH secretion/synthesis and reduce bone turnover, 
and could be particularly relevant in areas with widespread vitamin D deficiency as a cheap 
alternative.   
 
PTH suppression can be mediated by several mechanisms. 25(OH)D is substrate for renal 1- 
hydoxylase, which produces 1,25(OH)2D from circulating 25(OH)D, that binds to vitamin D 
receptor on parathyroid cells, to suppress the secretion of PTH.(24) This was supported by the 
finding that vitamin D supplementation led to an increase in levels of circulating 1,25 (OH)2 
D3. Parathyroid gland cells have also been shown to express 1- hydoxylase, which can 
suppress PTH by local production of 1,25 (OH)2 D3. Finally, an increase in calcium level can 
supress the PTH secretion, but whether the level can go down to the normal remains a matter 
of investigation. Though between group difference in serum uric acid levels was not 
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might modulate serum uric acid levels, as suggested in a recent report where elevated PTH was 
shown to impair uric acid excretion from kidneys and gut in CKD animals. (25) 
 
Increased FGF23 can inhibit the PTH expression, mediated by Klotho-FGFR1c activity in 
CKD subjects.(4) Elevated FGF23 levels are also associated with decrease in 1,25(OH)2D 
because of their suppressive effect on 1- hydroxylase.(22) In this context, the declining trend 
in FGF23 with vitamin D supplementation, and the positive correlation of change in FGF23 
with change in iPTH are of interest. Some studies have reported a rise in FGF23 level after 
supplementation of cholecalciferol (22) and paricalcitol.(23) In our study, fall in PTH levels and 
elevated 1.25 (OH) D would have had competing effects on FGF23. (26) The interactions of 
FGF23 with iPTH, 1,25(OH)2D and 25(OH) D is complicated and needs further investigation. 
 
Vitamin D deficiency is almost universal in CKD population. The recently updated KDIGO 
CKD-MBD Guidelines(27) make an ungraded recommendation to correct vitamin D deficiency 
in CKD subjects. Also, the exact protocol for correction is not well-defined. We used two doses 
of 300,000 IU 8 week apart, which effectively replenished the 25(OH)D levels accompanied 
by increase in active vitamin D and reduction in iPTH level and markers of bone turnover and 
no events of hypercalcemia and hyperphosphatemia. However, this strategy needs to be 
monitored for its long term impact. 
 
There are some limitations of our study which includes single centre design, exclusion of 
diabetic subjects, absence of bone biopsy, lack of assessment of dietary intake and urinary 
excretion of calcium and phosphate and a short duration of intervention and follow-up. The 
strength of this study is that it was randomised, double-blind, placebo-controlled study with 
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In conclusion, correction of vitamin D deficiency with cholecalciferol supplementation 
suppress secondary hyperparathyroidism and favourably change biochemical markers of 
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Table 1: Baseline characteristics of study subjects 
Parameters Placebo (n=59) Cholecalciferol (n=58) 
Gender (M/F) 40/19 41/17 
Age (years) 45.20±11.61 43.17±11.79 
Body mass index (kg/m2) 23.45±2.91 23.57±2.67 
Duration of disease (months) 32.30±46.94 39.53±49.71 
Number of subjects with 
proteinuria  
30 (51) 31(53) 
History of smoking 4 (7) 5 (9) 
Hypertension 54 (92) 53 (91) 
Cause of CKD 
Chronic Interstitial 
Nephritis 
11(19) 10 (17) 
Chronic 
Glomerulonephritis 
5 (8) 6 (10) 
Polycystic Kidney Disease 6 (10) 6 (10) 
Unknown 30 (51) 27 (47) 
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ACE inhibitors 23 (39) 24 (41) 
ARB 16 (27) 18 (31) 
Beta-blockers 17 (29) 20 (34) 
Statins 19 (32) 27 (47) 
Hypouricemic drugs 14 (24) 11 (19) 
Calcitriol 1 (2) 3 (5) 
Non-calcium based 
phosphate binders 
1 (2) 2 (3) 
Calcium based phosphate 
binders 
7 (12) 6 (10) 
Sodium bicarbonate 41 (69) 32 (55) 
Calcium-channel blockers 38 (64) 36 (62) 
Abbreviations: SBP, systolic blood pressur; DBP, diastolic blood pressure; CAD, coronary 
artery disease; CKD, chronic kidney disease; ACE, angiotensin converting enzyme; ARB, 
angiotensin II receptor blockers.  
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Table 2: Key laboratory findings and levels of circulating biomarkers in study subjects  
Parameter Placebo (n=59) Cholecalciferol 
(n=58) 
Hemoglobin (mmol/L) 7.46±1.20 7.43±1.05 
eGFR (min/ml/1.73m2) 34.63±12.25 35.77±12.37 
Albumin (g/L) 46.20±6.30 47.40±5.40 
Calcium (mmol/L) 2.27±0.23 2.25±0.13 
Inorganic Phosphorus (mmol/L) 1.30±0.45 1.18±0.29 
Uric Acid (µmol/L) 455.62±140.97 476.43±138.00 
25(OH)D (nmol/L) 32.97±11.93 33.45±4.42 
1,25 (OH)2 D(pmol/L) 50.19±31.30 47.67±27.53 
iPTH (pg/ml)* 146 (102, 247) 139(84, 212) 
iFGF-23 (pg/ml) * 57.66 (44.48, 88.90) 57.88 (41.42, 69.04) 
SAP (U/L) 136.07±59.83 135.17±58.32 
BAP (U/L)* 40.06 (29.34, 55.89) 37.59 (27.49, 52.56) 
CTX-1 (ng/ml)* 1.44 (1.00, 2.33) 1.45 (0.82, 2.23) 
Abbreviations: eGFR, estimated glomerular filtration rate; 25(OH)D, 25 hydroxy vitamin D; 
1,25 (OH)2 D, 1,25 di-hydroxy vitamin D; iPTH, intact parathyroid hormone; iFGF-23, intact 
fibroblast growth factor-23; SAP, total serum alkaline phosphatase; BAP, bone specific 
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Data presented as mean± standard deviation and median (25th, 75th percentile) 
*
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Table 3: Change in biochemical parameters and markers of bone turnover between baseline and 16 weeks 
  Placebo (n=59) Cholecalciferol (n=58) Between group difference 
 
  Mean change  
(95% CI) 
P value Mean change  
(95% CI) 
P value Difference of Mean change 
(95% CI) 
P value 
25(OH)D (nmol/L) 3.77 (-1.15 to 8.69) 0.13 62.18 (54.69 to 70.04) <0.001 58.41 (49.32 to 67.54) <0.001 
1,25 (OH)2 D 
(pmol/L) 
1.20 (-11.61 to 14.03) 0.85 38.59 (13.53 to 63.65) 0.003 37.39 (11.18 to 67.84) 0.007 
i-PTH (pg/ml) * 47.36 (6.63 to 88.10) 0.050 -53.37 (-82.37 to -24.36) <0.001 -100.73 (-150.50 to -50.95) <0.001 
iFGF-23 (pg/ml) * -7.33 (-24.10 to 9.45) 0.27 -14.71 (-28.45 to -0.97) 0.33 -7.38 (-28.92 to 14.15) 0.96 
SAP (U/L) 9.40 (-2.08 to 20.89) 0.11 -10.85 (-20.70 to -1.01) 0.031 -20.25 (-35.14 to -5.38) 0.008 
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CTX-I (ng/ml)* -0.09 (-0.22 to 0.02) 0.132 -0.31 (-0.42 to -0.20) <0.001 -0.21 (-0.38 to -0.05) 0.05 
eGFR 
(min/ml/1.73m2) 
1.57(-0.93 to 4.01) 0.21 1.42 (-0.55 to 3.40) 0.15 -0.15 (-3.31 to 3.01) 0.92 
Hemoglobin 
(mmol/L) 
-0.14 (-0.33 to 0.06) 0.18 -0.01 (-0.19 to 0.17) 0.94 0.13 (-0.14 to 0.39) 0.34 
Uric Acid (mmol/L) -30.33 (-39.85 to 4.76) 0.09 -35.69 (-66.12 to -1.78) 0.039 -5.36 (-52.94 to 42.82) 0.83 





-0.10 (-0.22 to 0.03) 0.12 0.06 (-0.06 to 0.19) 0.31 0.16 (-0.12 to 0.33) 0.07 
Abbreviations: eGFR, estimated glomerular filtration rate; 25(OH)D, 25 hydroxy vitamin D; 1,25 (OH)2 D, 1,25 di-hydroxy vitamin D; iPTH, 
intact parathyroid hormone; IL-6, interleukin-6; hs-CRP, high sensitivity C-reactive protein; iFGF-23, intact fibroblast growth factor-23; SAP, 
total serum alkaline phosphatase; BAP; bone specific alkaline phosphatase; CTX-I, C-terminal telopeptides of Type 1 collagen 
























Table 4: Percent change at 16 week from baseline in circulating biomarkers in study subjects  
Parameter Placebo (n=59) Cholecalciferol (n=58) P value 
25(OH)D  3.79 (-25.80, 34.89) 197.70 (116.18, 290.55) <0.0001 
1,25(OH)2 D -6.48 (-38.16, 49.66) 38.90 (-3.47, 158.03) 0.002 
iPTH  16.66 (-18.80, 93.56) -25.63 (-40.09,  1.87) <0.0001 
iFGF-23  -2.12 (-34.91, 49.66) -1.22 (-36.83,  17.09) 0.892 
SAP  0.00 (-4.46, 20.77) -10.44 (-22.04, 1.81) 0.001 
BAP  -5.36 (-38.20, 34.80) -29.96 (-61.77, 14.29) 0.025 
CTX-1  -2.92 (-27.33, 16.73) -18.02 (-41.02,  0.00) 0.008 
Calcium  -4.39 (-12.20, 3.33) 1.66 (-3.51, 9.06) 0.001 
Inorganic Phosphorus  -9.02 (-23.84, 13.86) 0.00 (-11.72, 21.87) 0.066 
Abbreviations: 25(OH)D, 25 hydroxy vitamin D; 1,25 (OH)2 D, 1,25 di-hydroxy vitamin D; 
iPTH, intact parathyroid hormone; iFGF-23, intact fibroblast growth factor-23; SAP, total 
serum alkaline phosphatase; BAP, bone specific alkaline phosphatase; CTX-I, C-terminal 
telopeptides of Type 1 collagen 
Data presented as median (25th, 75th percentile) 
























Table 5: Change in iPTH at 16 weeks based on gender, baseline vitamin D level tertiles and age group 
 
 
Placebo Cholecalciferol p value 
Gender  
Female N=19 
22.89 (-81.23 to 127.00) 
N=17 
-48.57(-110.38 to 13.25) 
0.402 
 Male N=40 
58.70 (19.71 to 97.69) 
N=41 
-55.36(-89.26 to -21.44) 




71.21 (-13.56 to 156.00) 
N=19 
-74.08 (-112.02 to -32.65) 
0.078 
 Tertile 2 
(10.09-16.67 ng/ml) 
N=18 
85.07 (0.94 to 169.21) 
N=21 




-8.82 (-52.30 to 34.66) 
N=18 
-26.69 (-66.63 to 13.22) 
Age group  
≤50 years N=40 
14.19 ( -30.88 to 59.36) 
N=40 
-72.34 (-112.02 to -32.65) 
0.435 
>50 years N=19 
118.94 (37.90 to 199.98) 
N=18 
-11.20 (-37.27 to 14.87) 
Data presented as mean (95% confidence interval), *p value for test of interaction between treatment and subgroup variables  
by general linear model. 
 
